













Thank you for answering the survey
Your special coupon is here
We send the November-only coupon on LINE.
Get the coupon on LINEAdd us as a friend for the coupon and booking
Everything continues on LINE
No clinic visits needed









GLP-1(M)
Decreased appetite, nausea, diarrhea, constipation, vomiting
GLP-1(M) is approved in Japan under the Pharmaceuticals and Medical Devices Act for type 2 diabetes, but its use for obesity treatment at our clinic is not approved in Japan.
We obtain medication approved in Japan from pharmaceutical wholesalers in Japan.
The Mounjaro used in this treatment is approved in Japan for type 2 diabetes, but its approved indications, dosage and administration differ from the purpose and method of use at our clinic.
An injectable GLP-1 receptor agonist has been approved by the U.S. FDA as an obesity treatment.
If a serious side effect occurs, it is not covered by Japan's Relief System for Sufferers from Adverse Drug Reactions.